HIMS Stock Analysis: Buy, Sell, or Hold?
HIMS - Hims & Hers Health, Inc.
$25.05
0.81 (3.34%)
▲
5d:
-11.39%
30d:
-7.19%
90d:
+53.68%
WAIT
LOW Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Smart Money Accumulation
HIMS is down 7.2% this week, but smart money is accumulating calls. Top strike: $40 2026-06-18 with 10,308 OI. Call ratio: 62% View Scanner →
Strength: 8.5/10
Get Alerted When HIMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
82 traders called HIMS this week
90% bullish • 10 bearish
90% bullish • 10 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: HIMS is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: HIMS is down 11.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$20.25
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$12.57
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HIMS is currently trading at $25.05, which is considered fair relative to its 30-day fair value range of $22.14 to $29.18. The stock's valuation (Forward PE: 43.3) is in line with its historical norms (40.9). At these levels, the market is pricing in 2.0% annual earnings growth.
Technical Outlook: Technically, HIMS is in a downtrend. Immediate support is located at $23.26, while resistance sits at $30.39. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HIMS is in a downtrend. Immediate support is located at $23.26, while resistance sits at $30.39. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$22.14 -
$29.18
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
75.7%
Protect Your Profits
Holding HIMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- NEUTRAL: Near Wall St target ($26.82)
- BULLISH: Expecting earnings turnaround to 2.0% growth with 3.8% revenue growth
- WARNING: Recommendation downgraded due to -11.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$22.14 -
$29.18
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$23.26
Resistance Level
$30.39
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
43.34
Wall Street Target
$26.82
(+7.1%)
Revenue Growth (YoY)
3.8%
Earnings Growth (YoY)
-17.4%
Profit Margin
-0.6%
Valuation Premium vs History
+2.0% premium
PE vs Historical
43.3 vs 40.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+2.0%
(market-implied from PE analysis)
1-Year Target
$25.55
(+2%)
2-Year Target
$26.06
(+4%)
3-Year Target
$26.58
(+6%)
3-Yr Target (if PE normalizes)
(PE: 43→41)
PE COMPRESSION
$25.09
(+0%)
Earnings growth offset by PE compression
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (57x PE), but valuation improves significantly next year (43x PE) as earnings recover.
Trailing PE: 57.14 | Current EPS (TTM): $0.51
Bull Case
$40.07
(+60%)
Analyst growth 25.0%, PE expands to 62.9
Base Case
$36.43
(+46%)
Market implied 25.0%, PE stable at 57.1
Bear Case
$19.82
(-21%)
Severe decline -20.0%, PE contracts to 48.6
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: May 15, 2026 9:43 PM ET
Data refreshes hourly during market hours. Next update: 10:43 PM
Data refreshes hourly during market hours. Next update: 10:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HIMS showing a specific setup today?
Insider Activity (6 Months)
1
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Soleil Boughton
SELL
9463 shares
2026-04-20
Oluyemi Okupe
SELL
19645 shares
2026-04-20
Oluyemi Okupe
SELL
18005 shares
2026-04-17
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
Advanced HIMS Option Strategies
Professional options setups generated by AI based on today's HIMS price and gamma walls.
